Search NLS News

Anette Weyergang, Senior Scientist and Project Group Leader at Oslo University Hospital, wants to make cancer treatment more effective and match the right patient with the right drug. Anette Weyergang is on the verge of creating a company to bring her cancer research into the world. Her discovery could make a real difference in how novel […]

When considering the significant industries in Norway, several obvious ones spring to mind: oil and gas, hydropower, property, and fishing. Life sciences would feature on very few lists, but that is slowly starting to change. The life science industry itself in Norway has been growing rapidly in recent years, with a focus on innovative technologies […]

The Norwegian company has submitted a cash offer to acquire all shares in Swedish Sensidose for approximately 75 million SEK. The offer is recommended by the independent bid committee of Sensidose. The Sensidose shares are currently listed on Spotlight Stock Market in Sweden. “This potential transaction is an excellent example of Navamedic’s proactive approach to […]

The study describes a novel method to directly extract membrane proteins from cells into lipid Salipro nanoparticles, enabling structure-function analysis using surface plasmon resonance (SPR) and cryo-electron microscopy (cryo-EM) for challenging drug targets. For this study, the teams leveraged GeneArt Gene-to-Protein Services, part of Thermo Fisher Scientific, for protein production with structure determination support from […]

SynAct Pharma’s recently acquired affiliate TXP Pharma was granted a patent in Canada related to “Alpha- and gamma-MSH analogues”. In addition, TXP’s patent application in another patent family relating to ”Exendin-4-analogues” has entered national phase in significant countries and regions worldwide. Read more: SynAct acquires TXP Pharma and carries out a directed share issue TXP […]

ObsERV identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients, notably of patients that are normally considered unresponsive to immunotherapy. In addition, the company has preclinically demonstrated complete tumor eradication in animal models when targeting […]

LINK Medical has announced the integration of Pharm Assist into the LINK Medical family. “We are very excited to have Pharm Assist integrate with our network of expert teams, especially strengthening our already robust regulatory group making us very unique in our industry. Our Regulatory team across the Nordics now has over 60 specialists, including […]

Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have […]

Calquence, a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China. “This approval for Calquence offers people living with mantle cell […]

The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform will be built around a selected high-productivity and state-of-the-art quality suspension-based HEK293 cell line, with full scalability to 200L […]